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by MicroRNA-21-mTOR-mediated inhibition p27 
protein degradation in gastric cancer
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Abstract 
Objective: Celastrol has anti‑cancer effects by increase of apoptosis of gastric cancer cells. However, its role in gastric 
cancer cell cycle is still unclear. The aim of this study was to investigate the effect and mechanism of celastrol on 
gastric cancer cell cycle.
Methods: The effects of celastrol on cell cycle in BGC‑823 and MGC‑803 cells were assayed via flow cytometry 
analysis. The expression of p27 and mTOR was detected by real‑time PCR and western blot. The activity of mTOR and 
mTORC2 was measured by mTOR and mTORC2 kinase assays. miR‑21 mimic was used to up‑regulate miR‑21 expres‑
sion and mTOR expression plasmid was used to increase mTOR level in gastric cancer cells.
Results: Celastrol caused G2/M cell‑cycle arrest that was accompanied by the down‑regulation of miR‑21 expression. 
In particular, miR‑21 overexpression reversed cell cycle arrest effects of celastrol. Further study showed that celastrol 
increased levels of the p27 protein by inhibiting its degradation. miR‑21 and mTOR signaling pathway was involved 
in the increase of p27 protein expression in BGC‑823 and MGC‑803 cells treated with celastrol. Significantly, miR‑21 
overexpression restored the decrease of mTOR activity in cells exposed celastrol.
Conclusions: The effect of celastrol on cell cycle arrest of gastric cancer cells was due to an increase of p27 protein 
level via inhibiting miR‑21‑mTOR signaling pathway.
Keywords: Celastrol, Cell cycle arrest, miR‑21, mTOR, p27
© 2015 Sha et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
There is increasing evidence demonstrating uncon-
trolled gastric cancer cell growth is due to disruption of 
the G1/S and G2/M checkpoints, which is involved in a 
series of positive and negative cell-cycle regulators [1, 2]. 
As a cyclin-dependent kinase inhibitor, p27 could nega-
tively modulate cell cycle progression through inhibition 
of the G2/M phase [3]. Accumulating evidence suggests 
p27 was a useful predictive marker of prognosis of gastric 
cancer. The decrease of p27 expression facilitates tumor 
growth and correlates with clinical invasiveness of the 
tumors, while high expression of p27 was associated with 
a favorable prognosis [4, 5]. Therefore, it is important to 
make clear the key molecular mechanism of regulating 
p27 in gastric cancer.
As an oncogene, microRNA-21 (miR-21) plays an 
important role in regulating gastric cancer cell prolifera-
tion and migration [6]. High miR-21 expression predicts 
poorer survival in patients with gastric cancer [7]. Fur-
thermore, overexpression of miR-21 is correlated with 
worse tumor differentiation, lymph node metastasis, 
and TNM stage [8]. When the expression of miR-21 was 
down-regulated in human gastric cancer, it was showed 
to inhibit cell proliferation [9].
The mammalian target of rapamycin (mTOR), a Ser/
Thr kinase, plays essential roles in the regulation of 
growth-related processes [10]. It has been reported that 
the mTOR signaling pathway is activated in gastric can-
cer [11]. Activated mTOR has been positively correlated 
with tumor progression and poor survival in patients 
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with gastric cancer [12, 13]. The mTOR inhibitor has 
been confirmed to induce cell cycle arrest and apoptosis 
of gastric cancer cell line [14]. Available clinical trial data 
show that the mTOR inhibitor is effective to treat gastric 
cancer patients in combination with chemotherapeutic 
agents [15].
Celastrol is a plant triterpene derived from the root of 
Thunder of God Vine and has anti-cancer effects [16]. 
Celastrol has also been found to induce apoptosis and 
autophagy of gastric cancer cells [17]. Our previous stud-
ies revealed that celastrol is capable of inducing apopto-
sis and inhibiting growth of gastric cancer cells through 
down-regulation of miR-21 expression [18]. However, 
whether celastrol exerts a negative effect role on gastric 
cancer cell cycle is still unclear. Therefore, in the present 
study, we investigated the effects and mechanisms of 
celastrol on cell cycle regulation. We hypothesized that 
celastrol induces cell cycle arrest of gastric cancer cells 
by modulating miR-21 expression and mTOR signaling 
pathway in BGC-823 and MGC-803 cells.
Results
Celastrol induced G2/M cycle arrest of gastric cancer cells
Our previous study showed that celastrol increased 
apoptosis of gastric cancer cells to exert anti-gastric can-
cer effect [19]. The growth of gastric cancer cells was sig-
nificantly decreased after treated with celastrol for 24 h. 
To analyze the effect of celastrol on cell cycle regulation, 
we treated BGC-823 and MGC-803 cells with 2 μM cel-
astrol and evaluated the cell distribution through the cell 
cycle. Celastrol induced the accumulation of cells in the 
G2/M phase and decreased the cell population in the G0/
G1 phases (Fig. 1a, b).
Consistent to our previous study [18], we found that 
miR-21 expression was decreased in BGC-823 and MGC-
803 cells treated with celastrol (data not shown).
Up‑regulation of miR‑21 can reverse the effect of celastrol 
on cell cycle arrest
This assay was conducted to investigate whether miR-
21 was involved in the effect of celastrol on cell cycle 
arrest in gastric cancer cells. In concordance with our 
prior findings, miR-21 mimic could reverse the increase 
of G2/M-phase and the decrease of the G0/G1-phase 
induced by celastrol in BGC-823 and MGC-803 cells 
(Fig. 2a, b).
Celastrol increased p27 protein level in gastric cancer cells 
through miR‑21
It has been reported that cell cycle regulators such as 
p21 and p27 have a particularly important role in anti-
proliferative effect on gastric cancer cells [20]. Therefore, 
to further explore the mechanism involved in cell cycle 
arrest by celastrol in gastric cancer cells, the effect of 
celastrol on p21 and p27 expression was determined. As 
shown in Fig.  3a, b, celastrol increased the p27 protein 
levels but had no effect on P27 mRNA levels in BGC-823 
and MGC-803 cells, indicating that celastrol upregulated 
the cellular level of p27 via a post-translational mecha-
nism. To confirm this hypothesis, we measured the sta-
bility of the p27 protein after celastrol (2 μM) treatment 
using cycloheximide (50 μg/mL) to block de novo protein 
synthesis. As expected, the rate of p27 protein degrada-
tion was significantly inhibited in gastric cancer cells 
treated with celastrol (Fig. 3c). However, the p21 protein 
expression was not altered by celastrol (Fig. 3a).
Next, we explored whether miR-21 was implicated 
in p27 protein degradation induced by celastrol. The 
results showed that transfection of miR-21 mimic could 
decrease p27 protein level in gastric cancer cells exposed 
to celastrol (Fig. 3d).
Celastrol inhibited mTOR activity through miR‑21
Increasing evidences suggested that mTOR can be acti-
vated by Akt signaling pathway in gastric cancer [21, 22]. 
Because celastrol inhibited PI3  K/Akt activation in our 
previous study [18], we hypothesized that celastrol might 
interrupt mTOR activity in gastric cancer cells. Treat-
ment of gastric cancer cells with celastrol significantly 
inhibited phosphorylation of mTOR, but did not affect 
total mTOR expression when compared with the con-
trol (Fig. 4a). In addition, we measured the mTOR activ-
ity by an mTOR kinase assay using recombinant protein. 
We observed that celastrol significantly decreased mTOR 
kinase activity, which could be reversed by miR-21 mimic 
(Fig.  4b). We also determined the effect of celastrol 
on mTORC2 immunoprecipitated from BGC-823 and 
MGC-803 cells lysates using a specific antibody against 
Rictor. The result also showed that mTORC2 kinase 
activity in BGC-823 and MGC-803 cells was significantly 
attenuated by celastrol administration (Fig.  4c). Similar 
to mTOR kinase activity, miR-21 mimic could restore the 
decrease of mTORC2 activity induced by celastrol.
Down‑regulation of miR‑21 expression can inhibit mTOR 
activity
To determine whether miR-21 can regulate mTOR sign-
aling pathway in gastric cancer cells, we investigated 
mTOR and mTORC2 kinase activity in cells transfected 
miR-21 inhibitor. The result showed that transfection of 
miR-21 inhibitor decreased mTOR and mTORC2 kinase 
activity as shown in Fig. 5a, b
Celastrol increased p27 expression through mTOR
In renal cell carcinoma cells, mTOR signaling increased 
the reduction of nuclear p27 protein levels [23]. Since 
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celastrol significantly inhibited mTOR activity, we 
wanted to investigate whether mTOR played a role in cel-
astrol regulating p27 protein degradation. Therefore, we 
transfected the mTORSL1+IT expression construct into 
BGC-823 and MGC-803 for 24 h, and then cultured the 
cells with or without celastrol for another 16  h. In gas-
tric cancer cells treated with celastrol for 16 h, p27 was 
significantly reduced, while activation of mTOR rescued 
this protein level dramatically (Fig. 6a). Figure 6b shows 
that p27 mRNA level was not regulated by activation of 
mTOR and/or with celastrol treatment. These results 
suggested that inhibition of mTOR activity could main-
tain p27 protein levels.
Discussion
The present report describes the molecular mechanism 
of cell cycle arrest induced by celastrol in human gas-
tric cancer cells. Celastrol induced G2/M cycle arrest of 
BGC-823 and MGC-803 cells and caused the decrease 
of mTOR activity and the increase of p27 protein expres-
sion. Furthermore, up-regulation of miR-21 expres-
sion can reverse G2/M cycle arrest gastric cancer cells 
induced by celastrol. We also found that celastrol inhib-
ited mTOR activity and enhanced p27 protein expression 
could be restored by up-regulation of miR-21 expression.
miR-21 is one of the most widely upregulated in a num-
ber of solid tumours, including gastric cancer [24]. The 
Fig. 1 Celastrol induced G2/M cycle arrest of gastric cancer cells. Celastrol (2 μM) induced the accumulation of cells in the G2/M phase and 
decreased the cell population in the G0/G1 phases in BGC‑823 (a) and MGC‑803 cells (b). **P < 0.01 vs. control group
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upregulation of miR-21 expression is positively related to 
shorter survival time and poorer prognosis in gastric can-
cer patients [25]. In gastric cancer cells, miR-21 not only 
inhibits apoptosis but also regulates cell cycle [8]. Thus, 
miR-21 is a therapeutic potential target for gastric cancer. 
Our previous study has demonstrated that celastrol can 
inhibit miR-21 expression and induce apoptosis of gastric 
cancer cells through miR-21 [18]. In the present study, 
our data showed that overexpression of miR-21 reversed 
a cell cycle arrest at G2/M phase induced by celastrol. 
These results suggest that celastrol induces cycle arrest of 
gastric cancer cell by inhibition of miR-21 expression.
We observed a strong upregulation of p27 but not 
p21 in celastrol-treated gastric cancer cells, indicat-
ing that promotion of p27 is important for celastrol 
regulation of cell cycle. Celastrol induced the increase 
of p27 protein levels but had no effect on p27 mRNA 
levels. In addition, the rate of p27 protein degradation 
was significantly decreased in BGC-823 and MGC-803 
treated with celastrol. These results indicated that celas-
trol treatment inhibits p27 expression primarily through 
a post-translational mechanism. Overexpression of miR-
21 almost completely prevented the effect of celastrol on 
p27 upregulation. According to these results, we draw 
Fig. 2 Up‑regulation of miR‑21 can reverse the effect of celastrol on cell cycle arrest. Flow cytometry analysis revealed that miR‑146a mimic 
reversed the increase of G2/M‑phase and the decrease of the G0/G1‑phase induced by celastrol in BGC‑823 (a) and MGC‑803 cells (b). *P < 0.01 vs. 
Pre‑NC
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a conclusion that celastrol increases p27 expression 
through miR-21.
Inhibition of the mTOR pathway suppressed the 
growth of gastric cancer in vitro and in vivo [26, 27]. In 
the present study, we demonstrated that celastrol mark-
edly suppressed mTOR activity through inhibition of 
miR-21 expression. Moreover, the finding that down-reg-
ulation of miR-21 expression can inhibit mTOR activity 
provides further evidence that inactivation of mTOR is 
mediated by miR-21 in gastric cancer cells treated with 
celastrol. Inactivation of mTOR can promote p27 expres-
sion in various tumor tissues [28–30]. We also found that 
rapamycin, the inhibitor of mTOR, increased p27 expres-
sion in BGC-823 and MGC-803 cells (data not shown). 
Activation of mTOR rescued the increase of p27 pro-
tein level induced by celastrol (Fig.  6a). Therefore, we 
Fig. 3 Celastrol increased p27 protein level in gastric cancer cells through miR‑21. Western blot showed that celastrol significantly increased p27 
protein level in BGC‑823and MGC‑803 cells (a). The real‑time PCR revealed that celastrol had no effect on p27 mRNA level in BGC‑823and MGC‑803 
cells (b). BGC‑823and MGC‑803 cells were treated without (control) or with celastrol for 24 h, at which time cycloheximide (50 μg/ml) was added 
for the indicated periods of time. All the treated cells were then harvested and lysed for western blot analyses to determine the protein levels of 
p27 and β‑actin (as a loading control). Representative immunoblots and a graph showing protein levels of p27 relative to β‑actin are shown (c). 
Western blot analyses revealed that miR‑21 mimic reversed the increase of p27 protein level in BGC‑823 and MGC‑803 cells treated with celastrol 
(d). **P < 0.01, indicate significant differences from the respective control groups
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concluded that inhibition of mTOR contributes to the 
effects of celastrol on increased p27 expression.
Conclusion
In this study, we established a primary relationship 
between celastrol and G2/M cycle arrest in BGC-823 
and MGC-803 cells here. Furthermore, we explored cel-
astrol-induced cycle arrest by miR-21-mTOR-p27 signal-
ing pathways in gastric cancer cells. These results suggest 




Dulbecco’s modified Eagle’s medium (DMEM), sodium 
pyruvate were from Gibco-BRL (Rockville, MD, USA). 
Fetal bovine serum (FBS) was from PAA Laborato-
ries (GmbH, Linz, Austria). Celastrol (purity  >  98  %) 
Fig. 4 Celastrol inhibited mTOR activity through miR‑21. Western blot showed that celastrol significantly decreased p‑mTOR level in BGC‑823and 
MGC‑803 cells (a). mTOR and mTORC2 kinase assays revealed that miR‑21 mimic reversed the decrease of mTOR (b) and mTORC2 (c) activity. 
**P < 0.01, indicate significant differences from the respective control groups
Fig. 5 Down‑regulation of miR‑21 expression can inhibit mTOR activity. mTOR and mTORC2 kinase assays revealed that miR‑21 inhibitor signifi‑
cantly reduced mTOR (a) and mTORC2 (b) activity. **P < 0.01, indicate significant differences from the respective control groups
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was purchased from Alexis Biochemicals (San Diego, 
CA, USA). Leucine (purity 99  %) and dimethylthi-
azoly-2, 5-diphenyltetrazolium bromide (MTT) were 
obtained from Sigma Aldrich. Antibodies against mTOR, 
p-mTOR, p-S6, p-p70S6k, and p-BAD were purchased 
from Cell Signaling Technology (Beverly, MA, USA). 
Anti-Rictor, anti-p27 and anti-β-actin antibodies were 
purchased from Santa Cruz Biotechnologies (Santa Cruz, 
CA, USA). K-LISA™ mTOR activity kit was obtained 
from Millipore (Boston, MA, USA). The Detergent Com-
patible (DC) Protein Assay kit was purchased from Bio-
Rad Laboratories (Hercules, CA, USA). The miRNeasy 
Mini kit, the miScript Reverse Transcription kit and the 
miScript SYBR Green PCR kit were purchased from Qia-
gen (Hilden, Germany).
Cell culture
Human gastric adenocarcinoma cell line BGC-823 and 
gastric mucinous adenocarcinoma cell line MGC-803 
were purchased from the Shanghai Institute of Cytobiol-
ogy in the Chinese Academy of Sciences. BGC-823 and 
MGC-803 cells were cultured as described previously [18, 
19]. All cell lines were maintained at 37 °C in a humidified 
incubator containing 5 % CO2 and treated with celastrol 
[dissolved in dimethyl sulphoxide (DMSO)] in complete 
DMEM medium. To obtain reliable results, the final con-
centration of DMSO in the culture medium was kept less 
than 0.1 %.
Flow cytometry analysis
Cell cycle was analyzed by flow cytometry analysis. 
Before treatment, serum was deprived for 24 h to syn-
chronize cell cycle. Then, serum was added back, and 
2 μM of celastrol was added. After treatment with cel-
astrol for 24  h, the cells were fixed with 80  % cooled 
ethanol, and incubated with 0.5  % Triton X-100 solu-
tion containing 1 mg ⁄ mL RNase A at 37 °C for 30 min. 
Next, propidium iodide (PI) was added into the wells 
at a final concentration of 50  μg ⁄ mL. Cellular DNA 
content was analyzed by a FACS (Becton Dickin-
son). Data were processed using Cell-Quest software 
(Becton–Dickinson).
Cell transfection
miR-21 was knocked down or overexpressed by trans-
fection with miRNA inhibitor or miRNA mimic using 
siPort Neo-FX (Ambion) according to the manufactur-
er’s recommendations. The sequence of miR-21 mim-
ics and miR-21 inhibitor were described as our previous 
report [18]. All of the oligonucleotides were synthesized 
Fig. 6 Celastrol increased p27 expression through mTOR. Western blot analyses revealed that mTORSL1+IT reversed the increase of p27 protein level 
in BGC‑823 and MGC‑803 cells treated with celastrol (a). The real‑time PCR revealed that mTORSL1+IT had no effect of p27 mRNA level in BGC‑823 
and MGC‑803 cells treated with celastrol (b)
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by RIBOBIO (Ribobio Co. Ltd, Guangzhou, China) and 
transfected at a final concentration of 100 nM.
The expression plasmid for pcDNA3.1-FLAG-
mTORSL1+IT plasmid (pYO293) was constructed as 
described previously [31]. Transient transfection was 
performed with LipofectAmine2000 (Invitrogen) accord-
ing to the manufacturer’s instructions.
Real‑time PCR
Approximately 5 ×  106 cells were treated without (con-
trol) or with celastrol for 12  h. RNA was isolated and 
purified using Trizol reagent (Invitrogen, USA), accord-
ing to manufacturer’s protocol. The p27 mRNA level 
was quantified by real-time PCR using TransStartTM 
SYBR Green qPCR Supermix (TransGen Biotech, Bei-
jing, China), and with GAPDH as an internal normal-
ized reference. For p27, the primers were as follows: 
forward, 5′-GTCAAACGTAAACAGCTCGAAT-3′ and 
reverse, 5′- TGCATAATGCTACATCCAACG-3′. For 
GAPDH, the primers were as follows: forward, 5′-TGGT-
GAAGGTCGGTGTGAAC-3′; and reverse, 5′-CCATG-
TAGTTG AGGTCAATGAAGG-3′.
Western blot analysis
BGC-823 and MGC-803 cells were treated without (con-
trol) or with celastrol for 24 h. Then, cells were lysed with 
ice-cold lysis buffer containing: 50  mmol/l Tris–HCl, 
pH 7.4; 1  % NP-40; 150  mmol/l NaCl; 1  mmol/l EDTA; 
1  mmol/l phenylmethylsulfonyl fluoride; and complete 
proteinase inhibitor mixture (one tablet per 10 ml; Roche 
Molecular Biochemicals, Indianapolis, IN, USA). Protein 
concentration in the cell lysate was quantified using the 
DC protein assay kit (Bio-Rad). After protein content 
determination using a DC Protein Assay kit, western blot 
analysis was performed. Rabbit anti-mTOR polyclonal 
antibody (pAb), rabbit anti-P-mTOR pAb and rabbit anti-
p27 pAb were diluted 1:1000. Mouse anti-β-Actin mono-
clonal antibody was diluted 1:5000.
mTOR and mTORC2 kinase assays
The in  vitro mTOR kinase assay was measured using 
K-LISA™ mTOR activity kit, which utilizes a p70S6k 
GST fusion protein as a specific mTOR substrate. The 
assay was performed in accordance with instructions 
provided by the manufacturers. mTORC2 kinase assays 
using immunoprecipitated rictor complex proteins 
from BGC-823 and MGC-803 cells were performed as 
described previously. Briefly, mTORC2 kinase assays 
were carried out at 37  °C for 30  min in 25  mM Hepes 
(pH 7.4), 100 mM potassium acetate, 1 mM MgCl2, and 
500  μM ATP, with rictor complex proteins as the sub-
strate [32].
Statistical analysis
Statistical analysis was performed with statistical analy-
sis software SPSS 13.0 software. Statistical analyses were 
performed using either an analysis of variance (ANOVA) 
or Student’s t test. Data were expressed as mean ± stand-
ard deviation. P < 0.05 was considered to be significant.
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